NCT06972875View on ClinicalTrials.gov

Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

February 28, 2027

Conditions
Prostate CAAndrogen Deprivation Therapy
Interventions
DRUG

Fezolinetant

Participants will receive fezolinetant for 28 days at FDA approved dosing and schedule of 45 mg po (per os/by mouth) once daily for treatment of hot flashes in menopausal women.

Trial Locations (1)

05401

University of Vermont Medical Center, Burlington

All Listed Sponsors
lead

University of Vermont

OTHER